CYP19A1 and breast carcinoma: In the SOLAR-1 phase II study (NCT03056755), patients with HR+/HER2− advanced breast cancer harboring PIK3CA mutations received alpelisib plus fulvestrant following CD4/6 inhibitor treatment with the aromatase inhibitor [30].